Skip to main content
Erschienen in: Pituitary 4/2014

01.08.2014

Characterization of persistent and recurrent Cushing’s disease

verfasst von: Nina K. Sundaram, Alessia Carluccio, Eliza B. Geer

Erschienen in: Pituitary | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

A case of possible recurrent Cushing’s disease (CD) is presented and data on current definitions of CD remission, persistence, and recurrence are reviewed. While prevailing guidelines recommend the use of serum cortisol in the first post-operative week for defining initial remission and predicting sustained remission, with the use of 24 h urinary free cortisol measurements if serum cortisol values are equivocal, there is debate as to which methods and thresholds best define CD remission and predict successful outcomes. Other methods used to define remission (and hence persistence and recurrence) include restoration of cortisol suppression after dexamethasone and physiologic diurnal cortisol rhythm as measured by midnight salivary free cortisol. However, the number and degree of abnormal test results needed to define recurrence, and the determination of which biochemical test has more significance when there are discrepancies between markers is inconsistent among studies. Further inquiry is warranted to examine if patients in apparent CD remission who have subtle hypothalamic pituitary adrenal (HPA) axis abnormalities represent distinctive remission subtypes versus mild or early recurrence. Additional investigation could also explore the degree to which these HPA axis abnormalities, such as alterations in cortisol circadian rhythm or partial resistance to dexamethasone, are associated with persistence of CD morbidities, including neuropsychiatric impairments, alterations in body composition, and cardiovascular risk.
Literatur
1.
Zurück zum Zitat Ambrosi B, Faglia G, the Multicenter Pituitary umor Study Group, Lombardia Region (1991) Epidemiology of pituitary tumors. In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A (eds) Pituitary adenomas: new trends in basic and clinical research. Excerpta Medica, Amsterdam, pp 159–168 Ambrosi B, Faglia G, the Multicenter Pituitary umor Study Group, Lombardia Region (1991) Epidemiology of pituitary tumors. In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A (eds) Pituitary adenomas: new trends in basic and clinical research. Excerpta Medica, Amsterdam, pp 159–168
2.
Zurück zum Zitat Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 40(4):479–484CrossRef Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 40(4):479–484CrossRef
3.
Zurück zum Zitat Plotz CM, Knowlton AI, Ragan C (1952) The natural history of Cushing’s syndrome. Am J Med 13(5):597–614PubMedCrossRef Plotz CM, Knowlton AI, Ragan C (1952) The natural history of Cushing’s syndrome. Am J Med 13(5):597–614PubMedCrossRef
4.
Zurück zum Zitat Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stella GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454–2462PubMedCentralPubMedCrossRef Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stella GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454–2462PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Boscaro M, Barzon L, Fallo F, Sonino N (2001) Cushing’s syndrome. Lancet 357(9258):783–791PubMedCrossRef Boscaro M, Barzon L, Fallo F, Sonino N (2001) Cushing’s syndrome. Lancet 357(9258):783–791PubMedCrossRef
6.
Zurück zum Zitat Newell-Price J, Trainer P, Besser M, Grossman A (1998) The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19(5):647–672PubMed Newell-Price J, Trainer P, Besser M, Grossman A (1998) The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19(5):647–672PubMed
7.
Zurück zum Zitat Findling JW, Raff H (2006) Cushing’s Syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 91(10):3746–3753PubMedCrossRef Findling JW, Raff H (2006) Cushing’s Syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 91(10):3746–3753PubMedCrossRef
8.
Zurück zum Zitat Starkman MN, Schteingart DE (1981) Neuropsychiatric manifestations of patients with Cushing’s syndrome. Relationship to cortisol and adrenocorticotropic hormone levels. Arch Intern Med 141(2):215–219PubMedCrossRef Starkman MN, Schteingart DE (1981) Neuropsychiatric manifestations of patients with Cushing’s syndrome. Relationship to cortisol and adrenocorticotropic hormone levels. Arch Intern Med 141(2):215–219PubMedCrossRef
9.
Zurück zum Zitat Dorn LD, Burgess ES, Dubbert B, Simpson SE, Friedman T, Kling M, Gold PW, Chrousos GP (1995) Psychopathology in patients with endogenous Cushing’s syndrome: “atypical” or melancholic features. Clin Endocrinol (Oxf) 43(4):433–442CrossRef Dorn LD, Burgess ES, Dubbert B, Simpson SE, Friedman T, Kling M, Gold PW, Chrousos GP (1995) Psychopathology in patients with endogenous Cushing’s syndrome: “atypical” or melancholic features. Clin Endocrinol (Oxf) 43(4):433–442CrossRef
10.
Zurück zum Zitat Chee GH, Mathias DB, James RA, Kendall-Taylor P (2001) Transsphenoidal pituitary surgery in Cushing’s disease: can we predict outcome? Clin Endocrinol (Oxf) 54(5):617–626CrossRef Chee GH, Mathias DB, James RA, Kendall-Taylor P (2001) Transsphenoidal pituitary surgery in Cushing’s disease: can we predict outcome? Clin Endocrinol (Oxf) 54(5):617–626CrossRef
11.
Zurück zum Zitat Estrada J, Garcia-Uria J, Lamas C, Alfaro J, Lucas T, Diez S, Salto L, Barcelo B (2001) The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 86(12):5695–5699PubMed Estrada J, Garcia-Uria J, Lamas C, Alfaro J, Lucas T, Diez S, Salto L, Barcelo B (2001) The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 86(12):5695–5699PubMed
12.
Zurück zum Zitat Pereira AM, van Aken MO, van Dulken H, Schutte PJ, Biermasz NR, Smit JW, Roelfsema F, Romijn JA (2003) Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing’s disease. J Clin Endocrinol Metab 88(12):5858–5864PubMedCrossRef Pereira AM, van Aken MO, van Dulken H, Schutte PJ, Biermasz NR, Smit JW, Roelfsema F, Romijn JA (2003) Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing’s disease. J Clin Endocrinol Metab 88(12):5858–5864PubMedCrossRef
13.
Zurück zum Zitat Carrasco CA, Coste J, Guignat L, Groussin L, Duque MA, Gaillard S, Bertagna X, Betherat J (2008) Midnight salivary cortisol determination for assessing the outcome of transsphenoidal surgery in Cushing’s disease. J Clin Endocrinol Metab 93(12):4728–4734PubMedCrossRef Carrasco CA, Coste J, Guignat L, Groussin L, Duque MA, Gaillard S, Bertagna X, Betherat J (2008) Midnight salivary cortisol determination for assessing the outcome of transsphenoidal surgery in Cushing’s disease. J Clin Endocrinol Metab 93(12):4728–4734PubMedCrossRef
14.
Zurück zum Zitat Valero R, Vallette-Kasic S, Conte-Devolx B, Jaquet P, Brue T (2004) The desmopressin test as a predictive factor of outcome after pituitary surgery for Cushing’s disease. Eur J Endocrinol 151(6):727–733PubMedCrossRef Valero R, Vallette-Kasic S, Conte-Devolx B, Jaquet P, Brue T (2004) The desmopressin test as a predictive factor of outcome after pituitary surgery for Cushing’s disease. Eur J Endocrinol 151(6):727–733PubMedCrossRef
15.
Zurück zum Zitat Salem V, Dhillo WS, Meeran K, Donaldson M, Martin NM (2010) Dexamethasone-suppressed corticotrophin-releasing hormone-stimulation test does not reliably diagnose or predict recurrence of Cushing disease. Clin Chem 56(6):1031–1034PubMedCrossRef Salem V, Dhillo WS, Meeran K, Donaldson M, Martin NM (2010) Dexamethasone-suppressed corticotrophin-releasing hormone-stimulation test does not reliably diagnose or predict recurrence of Cushing disease. Clin Chem 56(6):1031–1034PubMedCrossRef
16.
Zurück zum Zitat Schrell U, Fahlbusch R, Buchfelder M, Riedl S, Stalla GK, Muller OA (1987) Corticotropin-releasing hormone stimulation test before and after transsphenoidal selective microadenomectomy in 30 patients with Cushing’s disease. J Clin Endocrinol Metab 64(6):1150–1159PubMedCrossRef Schrell U, Fahlbusch R, Buchfelder M, Riedl S, Stalla GK, Muller OA (1987) Corticotropin-releasing hormone stimulation test before and after transsphenoidal selective microadenomectomy in 30 patients with Cushing’s disease. J Clin Endocrinol Metab 64(6):1150–1159PubMedCrossRef
17.
Zurück zum Zitat Shimon I, Ram Z, Cohen ZR, Hadani M (2002) Transsphenoidal surgery for Cushing’s disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 51(1):57–61 discussion 61-2PubMedCrossRef Shimon I, Ram Z, Cohen ZR, Hadani M (2002) Transsphenoidal surgery for Cushing’s disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 51(1):57–61 discussion 61-2PubMedCrossRef
18.
Zurück zum Zitat Hammer GD, Tyrell JB, Lamborn KR, Applebury CB, Hannegan ET, Bell S, Rahl R, Lu A, Wilson CB (2004) Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. J Clin Endocrinol Metab 89(12):6348–6357PubMedCrossRef Hammer GD, Tyrell JB, Lamborn KR, Applebury CB, Hannegan ET, Bell S, Rahl R, Lu A, Wilson CB (2004) Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. J Clin Endocrinol Metab 89(12):6348–6357PubMedCrossRef
19.
Zurück zum Zitat Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B (2005) Long-term remission rates after pituitary surgery for Cushing’s disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 63(5):549–559CrossRef Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B (2005) Long-term remission rates after pituitary surgery for Cushing’s disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 63(5):549–559CrossRef
20.
Zurück zum Zitat Chen JC, Amar AP, Choi S, Singer P, Couldwell WT, Weiss MH (2003) Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. J Neurosurg 98(5):967–973PubMedCrossRef Chen JC, Amar AP, Choi S, Singer P, Couldwell WT, Weiss MH (2003) Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. J Neurosurg 98(5):967–973PubMedCrossRef
21.
Zurück zum Zitat Esposito F, Dusick JR, Cohan P, Moftakhar P, McArthur D, Wang C, Swerdloff RS, Kelly DF (2006) Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 91(1):7–13PubMedCrossRef Esposito F, Dusick JR, Cohan P, Moftakhar P, McArthur D, Wang C, Swerdloff RS, Kelly DF (2006) Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 91(1):7–13PubMedCrossRef
22.
Zurück zum Zitat Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF (2002) Long-term follow-up results of transsphenoidal surgery for Cushing’s disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf) 56(4):541–551CrossRef Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF (2002) Long-term follow-up results of transsphenoidal surgery for Cushing’s disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf) 56(4):541–551CrossRef
23.
Zurück zum Zitat Yap LB, Turner HE, Adams CB, Wass JA (2002) Undetectable postoperative cortisol does not always predict long-term remission in Cushing’s disease: a single centre audit. Clin Endocrinol (Oxf) 56(1):25–31CrossRef Yap LB, Turner HE, Adams CB, Wass JA (2002) Undetectable postoperative cortisol does not always predict long-term remission in Cushing’s disease: a single centre audit. Clin Endocrinol (Oxf) 56(1):25–31CrossRef
24.
Zurück zum Zitat McCance DR, Besser M, Atkinson AB (1996) Assessment of cure after transsphenoidal surgery for Cushing’s disease. Clin Endocrinol (Oxf) 44(1):1–6CrossRef McCance DR, Besser M, Atkinson AB (1996) Assessment of cure after transsphenoidal surgery for Cushing’s disease. Clin Endocrinol (Oxf) 44(1):1–6CrossRef
25.
Zurück zum Zitat Trainer PJ, Lawrie HS, Verhelst J, Howlett TA, Lowe DG, Grossman AB, Savage MO, Afshar F, Besser GM (1993) Transsphenoidal resection in Cushing’s disease: undetectable serum cortisol as the definition of successful treatment. Clin Endocrinol (Oxf) 38(1):73–78CrossRef Trainer PJ, Lawrie HS, Verhelst J, Howlett TA, Lowe DG, Grossman AB, Savage MO, Afshar F, Besser GM (1993) Transsphenoidal resection in Cushing’s disease: undetectable serum cortisol as the definition of successful treatment. Clin Endocrinol (Oxf) 38(1):73–78CrossRef
26.
Zurück zum Zitat Pieters GF, Hermus AR, Meijer E, Smals AG, Kloppenborg PW (1989) Predictive factors for initial cure and relapse rate after pituitary surgery for Cushing’s disease. J Clin Endocrinol Metab 69(6):1122–1126PubMedCrossRef Pieters GF, Hermus AR, Meijer E, Smals AG, Kloppenborg PW (1989) Predictive factors for initial cure and relapse rate after pituitary surgery for Cushing’s disease. J Clin Endocrinol Metab 69(6):1122–1126PubMedCrossRef
27.
Zurück zum Zitat Locatelli M, Vance ML, Laws ER (2005) Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 90(9):5478–5482PubMedCrossRef Locatelli M, Vance ML, Laws ER (2005) Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 90(9):5478–5482PubMedCrossRef
28.
Zurück zum Zitat Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L, Laws ER (2008) Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93(2):358–362PubMedCrossRef Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L, Laws ER (2008) Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93(2):358–362PubMedCrossRef
29.
Zurück zum Zitat Alexandraki KI, Kaltsas GA, Isidori AM, Storr HL, Afshar F, Sabin I, Akker SA, Chew SL, Drake WM, Monson JP, Besser GM, Grossman AB (2013) Long-term remission and recurrence rates in Cushing’s disease: predictive factors in a single-centre study. Eur J Endocrinol 168(4):639–648PubMedCrossRef Alexandraki KI, Kaltsas GA, Isidori AM, Storr HL, Afshar F, Sabin I, Akker SA, Chew SL, Drake WM, Monson JP, Besser GM, Grossman AB (2013) Long-term remission and recurrence rates in Cushing’s disease: predictive factors in a single-centre study. Eur J Endocrinol 168(4):639–648PubMedCrossRef
30.
Zurück zum Zitat Hofmann BM, Hlavac M, Martinez R, Buchfelder M, Muller OA, Fahlbusch R (2008) Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg 108(1):9–18PubMedCrossRef Hofmann BM, Hlavac M, Martinez R, Buchfelder M, Muller OA, Fahlbusch R (2008) Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg 108(1):9–18PubMedCrossRef
31.
Zurück zum Zitat Toms GC, McCarthy MI, Nieven MJ, Orteu CH, King TT, Monson JP (1993) Predicting relapse after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 76(2):291–294PubMed Toms GC, McCarthy MI, Nieven MJ, Orteu CH, King TT, Monson JP (1993) Predicting relapse after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 76(2):291–294PubMed
32.
Zurück zum Zitat Valassi E, Biller BM, Swearingen B, Pecori Giraldi F, Losa M, Mortini P, Hayden D, Cavagnini F, Klibanski A (2010) Delayed remission after transsphenoidal surgery in patients with Cushing’s disease. J Clin Endocrinol Metab 95(2):601–610PubMedCentralPubMedCrossRef Valassi E, Biller BM, Swearingen B, Pecori Giraldi F, Losa M, Mortini P, Hayden D, Cavagnini F, Klibanski A (2010) Delayed remission after transsphenoidal surgery in patients with Cushing’s disease. J Clin Endocrinol Metab 95(2):601–610PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Bochicchio D, Losa M, Buchfelder M (1995) Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s Disease Survey Group. J Clin Endocrinol Metab 80(11):3114–3120PubMed Bochicchio D, Losa M, Buchfelder M (1995) Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s Disease Survey Group. J Clin Endocrinol Metab 80(11):3114–3120PubMed
34.
Zurück zum Zitat Newell-Price J, Trainer P, Besser M, Grossman A (1998) The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19(5):647–672PubMed Newell-Price J, Trainer P, Besser M, Grossman A (1998) The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19(5):647–672PubMed
35.
Zurück zum Zitat Kidambi S, Raff H, Findling JW (2007) Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing’s syndrome. Eur J Endocrinol 157(6):725–731PubMedCrossRef Kidambi S, Raff H, Findling JW (2007) Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing’s syndrome. Eur J Endocrinol 157(6):725–731PubMedCrossRef
36.
Zurück zum Zitat Raff H, Raff JL, Findling JW (1998) Late-night salivary cortisol as a screening test for Cushing’s syndrome. J Clin Endocrinol Metab 83(8):2681–2686PubMed Raff H, Raff JL, Findling JW (1998) Late-night salivary cortisol as a screening test for Cushing’s syndrome. J Clin Endocrinol Metab 83(8):2681–2686PubMed
37.
Zurück zum Zitat Putignano P, Toja P, Dubini A, Pecori Giraldi F, Corsello SM, Cavagnini F (2003) Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing’s syndrome. J Clin Endocrinol Metab 88(9):4153–4157PubMedCrossRef Putignano P, Toja P, Dubini A, Pecori Giraldi F, Corsello SM, Cavagnini F (2003) Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing’s syndrome. J Clin Endocrinol Metab 88(9):4153–4157PubMedCrossRef
38.
Zurück zum Zitat Hofmann BM, Hlavac M, Kreutzer J, Grabenbauer G, Fahlbusch R (2006) Surgical treatment of recurrent Cushing’s disease. Neurosurgery 58(6):1108–1118 discussion 1108–1118PubMedCrossRef Hofmann BM, Hlavac M, Kreutzer J, Grabenbauer G, Fahlbusch R (2006) Surgical treatment of recurrent Cushing’s disease. Neurosurgery 58(6):1108–1118 discussion 1108–1118PubMedCrossRef
39.
Zurück zum Zitat Dickerman RD, Oldfield EH (2002) Basis of persistent and recurrent Cushing disease: an analysis of findings at repeated pituitary surgery. J Neurosurg 97(6):1343–1349PubMedCrossRef Dickerman RD, Oldfield EH (2002) Basis of persistent and recurrent Cushing disease: an analysis of findings at repeated pituitary surgery. J Neurosurg 97(6):1343–1349PubMedCrossRef
40.
Zurück zum Zitat Nakane T, Kuwayama A, Watanabe M, Takahashi T, Kato T, Ichihara K, Kageyama N (1987) Long term results of transsphenoidal adenomectomy in patients with Cushing’s disease. Neurosurgery 21(2):218–222PubMedCrossRef Nakane T, Kuwayama A, Watanabe M, Takahashi T, Kato T, Ichihara K, Kageyama N (1987) Long term results of transsphenoidal adenomectomy in patients with Cushing’s disease. Neurosurgery 21(2):218–222PubMedCrossRef
41.
Zurück zum Zitat Benveniste RJ et al (2005) Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg 102(6):1004–1012PubMedCrossRef Benveniste RJ et al (2005) Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg 102(6):1004–1012PubMedCrossRef
42.
Zurück zum Zitat Hofmann BM, Fahlbusch R (2006) Treatment of Cushing’s disease: a retrospective clinical study of the latest 100 cases. Front Horm Res 34:158–184PubMedCrossRef Hofmann BM, Fahlbusch R (2006) Treatment of Cushing’s disease: a retrospective clinical study of the latest 100 cases. Front Horm Res 34:158–184PubMedCrossRef
43.
Zurück zum Zitat Knappe UJ, Lüdecke DK (1996) Persistent and recurrent hypercortisolism after transsphenoidal surgery for Cushing’s disease. Acta Neurochir Suppl 65:31–34PubMed Knappe UJ, Lüdecke DK (1996) Persistent and recurrent hypercortisolism after transsphenoidal surgery for Cushing’s disease. Acta Neurochir Suppl 65:31–34PubMed
44.
Zurück zum Zitat Friedman RB, Oldfield RB, Nieman LK, Chrousos GP, Doppman JL, Cutler GB, Loriaux DL (1989) Repeat transsphenoidal surgery for Cushing’s disease. J Neurosurg 71(4):520–527PubMedCrossRef Friedman RB, Oldfield RB, Nieman LK, Chrousos GP, Doppman JL, Cutler GB, Loriaux DL (1989) Repeat transsphenoidal surgery for Cushing’s disease. J Neurosurg 71(4):520–527PubMedCrossRef
45.
Zurück zum Zitat Knappe UJ, Lüdecke DK (1996) Transnasal microsurgery in children and adolescents with Cushing’s disease. Neurosurgery 39(3):484–492 discussion 492–493PubMed Knappe UJ, Lüdecke DK (1996) Transnasal microsurgery in children and adolescents with Cushing’s disease. Neurosurgery 39(3):484–492 discussion 492–493PubMed
46.
Zurück zum Zitat Patil CG, Veeravagu A, Prevedello DM, Katznelson L, Vance ML, Laws ER (2008) Outcomes after repeat transsphenoidal surgery for recurrent Cushing’s disease. Neurosurgery 63(2):266–270 discussion 270–271PubMedCrossRef Patil CG, Veeravagu A, Prevedello DM, Katznelson L, Vance ML, Laws ER (2008) Outcomes after repeat transsphenoidal surgery for recurrent Cushing’s disease. Neurosurgery 63(2):266–270 discussion 270–271PubMedCrossRef
47.
Zurück zum Zitat Estrada J, Boronat M, Mielgo M, Magallón R, Millan I, Díez S, Lucas T, Barceló B (1997) The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med 336(3):172–177PubMedCrossRef Estrada J, Boronat M, Mielgo M, Magallón R, Millan I, Díez S, Lucas T, Barceló B (1997) The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med 336(3):172–177PubMedCrossRef
48.
Zurück zum Zitat McLaughlin N, Kassam AB, Prevedello DM, Kelly DF (2011) Management of Cushing’s disease after failed surgery–a review. Can J Neurol Sci 38(1):12–21PubMed McLaughlin N, Kassam AB, Prevedello DM, Kelly DF (2011) Management of Cushing’s disease after failed surgery–a review. Can J Neurol Sci 38(1):12–21PubMed
49.
Zurück zum Zitat Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER (2000) Radiosurgery for Cushing’s disease after failed transsphenoidal surgery. J Neurosurg 93(5):738–742PubMedCrossRef Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER (2000) Radiosurgery for Cushing’s disease after failed transsphenoidal surgery. J Neurosurg 93(5):738–742PubMedCrossRef
50.
Zurück zum Zitat Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML (2007) Gamma Knife surgery for Cushing’s disease. J Neurosurg 106(6):980–987PubMedCrossRef Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML (2007) Gamma Knife surgery for Cushing’s disease. J Neurosurg 106(6):980–987PubMedCrossRef
51.
Zurück zum Zitat Castinetti F, Nagai M, Dufour H, Kuhn JM, Morange I, Jaquet P, Conte-Devolx B, Regis J, Brue T (2007) Gamma knife radiosurgery is a successful adjunctive treatment in Cushing’s disease. Eur J Endocrinol 156(1):91–98PubMedCrossRef Castinetti F, Nagai M, Dufour H, Kuhn JM, Morange I, Jaquet P, Conte-Devolx B, Regis J, Brue T (2007) Gamma knife radiosurgery is a successful adjunctive treatment in Cushing’s disease. Eur J Endocrinol 156(1):91–98PubMedCrossRef
52.
Zurück zum Zitat Aghi MK, Petit J, Chapman P, Loeffler J, Klibanski A, Biller BK, Swearingen B (2008) Management of recurrent and refractory Cushing’s disease with reoperation and/or proton beam radiosurgery. Clin Neurosurg 55:141–144PubMed Aghi MK, Petit J, Chapman P, Loeffler J, Klibanski A, Biller BK, Swearingen B (2008) Management of recurrent and refractory Cushing’s disease with reoperation and/or proton beam radiosurgery. Clin Neurosurg 55:141–144PubMed
53.
Zurück zum Zitat Petit JH, Biller BK, Yock TI, Swearingen B, Coen JJ, Chapman P, Ancukiewicz M, Bussiere M, Klibanski A, Loeffler JS (2008) Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab 93(2):393–399PubMedCrossRef Petit JH, Biller BK, Yock TI, Swearingen B, Coen JJ, Chapman P, Ancukiewicz M, Bussiere M, Klibanski A, Loeffler JS (2008) Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab 93(2):393–399PubMedCrossRef
54.
Zurück zum Zitat Kelly DF (2007) Transsphenoidal surgery for Cushing’s disease: a review of success rates, remission predictors, management of failed surgery, and Nelson’s Syndrome. Neurosurg Focus 23(3):E5PubMedCrossRef Kelly DF (2007) Transsphenoidal surgery for Cushing’s disease: a review of success rates, remission predictors, management of failed surgery, and Nelson’s Syndrome. Neurosurg Focus 23(3):E5PubMedCrossRef
55.
Zurück zum Zitat Chow JT, Thompson GB, Grant CS, Farley DR, Richards ML, Young WF (2008) Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing’s syndrome: a review of the Mayo Clinic experience. Clin Endocrinol (Oxf) 68(4):513–519CrossRef Chow JT, Thompson GB, Grant CS, Farley DR, Richards ML, Young WF (2008) Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing’s syndrome: a review of the Mayo Clinic experience. Clin Endocrinol (Oxf) 68(4):513–519CrossRef
56.
Zurück zum Zitat Thompson SK, Hayman AV, Ludlam WH, Deveney CW, Loriaux DL, Sheppard BC (2007) Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing’s disease: a 10-year experience. Ann Surg 245(5):790–794PubMedCentralPubMedCrossRef Thompson SK, Hayman AV, Ludlam WH, Deveney CW, Loriaux DL, Sheppard BC (2007) Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing’s disease: a 10-year experience. Ann Surg 245(5):790–794PubMedCentralPubMedCrossRef
57.
Zurück zum Zitat Assié G, Bahurel H, Coste J, Silvera S, Kujas M, Dugué MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushing’s Disease: a reappraisal of Nelson’s Syndrome. J Clin Endocrinol Metab 92(1):172–179PubMedCrossRef Assié G, Bahurel H, Coste J, Silvera S, Kujas M, Dugué MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushing’s Disease: a reappraisal of Nelson’s Syndrome. J Clin Endocrinol Metab 92(1):172–179PubMedCrossRef
58.
Zurück zum Zitat Brunicardi FC, Rosman PM, Lesser KL, Andersen DK (1985) Current status of adrenalectomy for Cushing’s disease. Surgery 98(6):1127–1134PubMed Brunicardi FC, Rosman PM, Lesser KL, Andersen DK (1985) Current status of adrenalectomy for Cushing’s disease. Surgery 98(6):1127–1134PubMed
59.
Zurück zum Zitat Sonino N, Zielezney M, Fava GA, Fallo F, Boscaro M (1996) Risk factors and long-term outcome in pituitary-dependent Cushing’s disease. J Clin Endocrinol Metab 81(7):2647–2652PubMed Sonino N, Zielezney M, Fava GA, Fallo F, Boscaro M (1996) Risk factors and long-term outcome in pituitary-dependent Cushing’s disease. J Clin Endocrinol Metab 81(7):2647–2652PubMed
60.
Zurück zum Zitat Miller JW, Crapo L (1993) The medical treatment of Cushing’s syndrome. Endocr Rev 14(4):443–458PubMedCrossRef Miller JW, Crapo L (1993) The medical treatment of Cushing’s syndrome. Endocr Rev 14(4):443–458PubMedCrossRef
61.
Zurück zum Zitat Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T (2008) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol 158(1):91–99PubMedCrossRef Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T (2008) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol 158(1):91–99PubMedCrossRef
62.
Zurück zum Zitat Sonino N, Boscaro M (1999) Medical therapy for Cushing’s disease. Endocrinol Metab Clin North Am 28(1):211–222PubMedCrossRef Sonino N, Boscaro M (1999) Medical therapy for Cushing’s disease. Endocrinol Metab Clin North Am 28(1):211–222PubMedCrossRef
63.
Zurück zum Zitat Sonino N, Boscaro M, Fallo F (2005) Pharmacologic management of Cushing syndrome: new targets for therapy. Treat Endocrinol 4(2):87–94PubMedCrossRef Sonino N, Boscaro M, Fallo F (2005) Pharmacologic management of Cushing syndrome: new targets for therapy. Treat Endocrinol 4(2):87–94PubMedCrossRef
65.
Zurück zum Zitat Hale AC, Coates PJ, Doniach I, Howlett TA, Grossman A, Rees LH, Besser GM (1988) A bromocriptine-responsive corticotroph adenoma secreting alpha-MSH in a patient with Cushing’s disease. Clin Endocrinol (Oxf) 28(2):215–223CrossRef Hale AC, Coates PJ, Doniach I, Howlett TA, Grossman A, Rees LH, Besser GM (1988) A bromocriptine-responsive corticotroph adenoma secreting alpha-MSH in a patient with Cushing’s disease. Clin Endocrinol (Oxf) 28(2):215–223CrossRef
66.
Zurück zum Zitat Koppeschaar HP, Croughs RJ, Thijssen JH, Schwarz F (1986) Response to neurotransmitter modulating drugs in patients with Cushing’s disease. Clin Endocrinol (Oxf) 25(6):661–667CrossRef Koppeschaar HP, Croughs RJ, Thijssen JH, Schwarz F (1986) Response to neurotransmitter modulating drugs in patients with Cushing’s disease. Clin Endocrinol (Oxf) 25(6):661–667CrossRef
67.
Zurück zum Zitat Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro MLDB, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SWJ (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89(5):2452–2462PubMedCrossRef Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro MLDB, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SWJ (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89(5):2452–2462PubMedCrossRef
68.
Zurück zum Zitat Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SWJ, Colao A (2009) The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223–230PubMedCrossRef Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SWJ, Colao A (2009) The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223–230PubMedCrossRef
69.
Zurück zum Zitat Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A (2010) Cabergoline monotherapy in the long-term treatment of Cushing’s disease. Eur J Endocrinol 163(5):709–716PubMedCrossRef Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A (2010) Cabergoline monotherapy in the long-term treatment of Cushing’s disease. Eur J Endocrinol 163(5):709–716PubMedCrossRef
70.
Zurück zum Zitat Colao A, Petersenn S, Newell-Price J (2011) Pasireotide (SOM230) demonstrates efficacy in patients with Cushing disease: results from a large, randomized-dose, double-blind, phase III study. in ENDO 2011. Boston Colao A, Petersenn S, Newell-Price J (2011) Pasireotide (SOM230) demonstrates efficacy in patients with Cushing disease: results from a large, randomized-dose, double-blind, phase III study. in ENDO 2011. Boston
71.
Zurück zum Zitat Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, Pasireotide B2305 Study Group (2012) A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366(10):914–924PubMedCrossRef Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, Pasireotide B2305 Study Group (2012) A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366(10):914–924PubMedCrossRef
72.
Zurück zum Zitat Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C, SEISMIC Study Investigators (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab 97(6):2039–2049PubMedCrossRef Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C, SEISMIC Study Investigators (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab 97(6):2039–2049PubMedCrossRef
73.
Zurück zum Zitat Blevins LS, Christy JH, Khajavi M, Tindall GT (1998) Outcomes of therapy for Cushing’s disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 83(1):63–67PubMed Blevins LS, Christy JH, Khajavi M, Tindall GT (1998) Outcomes of therapy for Cushing’s disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 83(1):63–67PubMed
74.
Zurück zum Zitat Barbetta L, Dall’Asta C, Tomei G, Locatelli M, Giovanelli M, Ambrosi B (2001) Assessment of cure and recurrence after pituitary surgery for Cushing’s disease. Acta Neurochir (Wein) 143(5):477–481 discussion 481-482CrossRef Barbetta L, Dall’Asta C, Tomei G, Locatelli M, Giovanelli M, Ambrosi B (2001) Assessment of cure and recurrence after pituitary surgery for Cushing’s disease. Acta Neurochir (Wein) 143(5):477–481 discussion 481-482CrossRef
75.
Zurück zum Zitat Rollin GA, Ferreira NP, Junges M, Gross JL, Czepielewski MA (2004) Dynamics of serum cortisol levels after transsphenoidal surgery in a cohort of patients with Cushing’s disease. J Clin Endocrinol Metab 89(3):1131–1139PubMedCrossRef Rollin GA, Ferreira NP, Junges M, Gross JL, Czepielewski MA (2004) Dynamics of serum cortisol levels after transsphenoidal surgery in a cohort of patients with Cushing’s disease. J Clin Endocrinol Metab 89(3):1131–1139PubMedCrossRef
76.
Zurück zum Zitat Boggan JE, Tyrrell JB, Wilson CB (1983) Transsphenoidal microsurgical management of Cushing’s disease. Report of 100 cases. J Neurosurg 59(2):195–200PubMedCrossRef Boggan JE, Tyrrell JB, Wilson CB (1983) Transsphenoidal microsurgical management of Cushing’s disease. Report of 100 cases. J Neurosurg 59(2):195–200PubMedCrossRef
77.
Zurück zum Zitat Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F (1999) Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 84(2):440–448PubMed Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F (1999) Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 84(2):440–448PubMed
78.
Zurück zum Zitat Castinetti F, Martinie M, Morange I, Dufour H, Sturm N, Passagia JG, Conte-Devolx B, Chabre O, Brue T (2009) A combined dexamethasone desmopressin test as an early marker of postsurgical recurrence in Cushing’s disease. J Clin Endocrinol Metab 94(6):1897–1903PubMedCrossRef Castinetti F, Martinie M, Morange I, Dufour H, Sturm N, Passagia JG, Conte-Devolx B, Chabre O, Brue T (2009) A combined dexamethasone desmopressin test as an early marker of postsurgical recurrence in Cushing’s disease. J Clin Endocrinol Metab 94(6):1897–1903PubMedCrossRef
79.
Zurück zum Zitat Valassi E, Crespo I, Santos A, Webb SM (2012) Clinical consequences of Cushing’s syndrome. Pituitary 15(3):319–329PubMedCrossRef Valassi E, Crespo I, Santos A, Webb SM (2012) Clinical consequences of Cushing’s syndrome. Pituitary 15(3):319–329PubMedCrossRef
80.
Zurück zum Zitat Leong GM, Abad V, Charmandari E, Reynolds JC, Hill S, Chrousos GP, Nieman LK (2007) Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. J Bone Miner Res 22:110–118PubMedCrossRef Leong GM, Abad V, Charmandari E, Reynolds JC, Hill S, Chrousos GP, Nieman LK (2007) Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. J Bone Miner Res 22:110–118PubMedCrossRef
81.
Zurück zum Zitat Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Farrerons J, Webb SM (2009) Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing’s syndrome. J Clin Endocrinol Metab 94(9):3365–3371PubMedCrossRef Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Farrerons J, Webb SM (2009) Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing’s syndrome. J Clin Endocrinol Metab 94(9):3365–3371PubMedCrossRef
82.
Zurück zum Zitat Krsek M, Silha JV, Jezková J, Hána V, Marek J, Weiss V, Stepán JJ, Murphy LJ (2004) Adipokine levels in Cushing’s syndrome; elevated resistin levels in female patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 60(3):350–357CrossRef Krsek M, Silha JV, Jezková J, Hána V, Marek J, Weiss V, Stepán JJ, Murphy LJ (2004) Adipokine levels in Cushing’s syndrome; elevated resistin levels in female patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 60(3):350–357CrossRef
83.
Zurück zum Zitat Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G (1999) Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 84(8):2664–2672PubMed Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G (1999) Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 84(8):2664–2672PubMed
84.
Zurück zum Zitat Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJSA, Wassenaar MJ, Middelkoop HAM, Pereira AM, Romijn JA (2010) Subtle cognitive impairments in patients with long-term cure of Cushing’s disease. J Clin Endocrinol Metab 95(6):2699–2714PubMedCrossRef Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJSA, Wassenaar MJ, Middelkoop HAM, Pereira AM, Romijn JA (2010) Subtle cognitive impairments in patients with long-term cure of Cushing’s disease. J Clin Endocrinol Metab 95(6):2699–2714PubMedCrossRef
85.
Zurück zum Zitat Hook JN, Giordani B, Schteingart DE, Guire K, Giles J, Ryan K, Gebarski SS, Langenecker SA, Starkman MN (2007) Patterns of cognitive change over time and relationship to age following successful treatment of Cushing’s disease. J Int Neuropsychol Soc 13(1):21–29PubMed Hook JN, Giordani B, Schteingart DE, Guire K, Giles J, Ryan K, Gebarski SS, Langenecker SA, Starkman MN (2007) Patterns of cognitive change over time and relationship to age following successful treatment of Cushing’s disease. J Int Neuropsychol Soc 13(1):21–29PubMed
86.
Zurück zum Zitat Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP (1997) The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 82(3):912–919PubMed Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP (1997) The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 82(3):912–919PubMed
87.
Zurück zum Zitat Tiemensma J, Biermasz NR, Middelkoop HAM, van der Mast RC, Romijn JA, Pereira AM (2010) Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing’s disease. J Clin Endocrinol Metab 95(10):E129–E141PubMedCrossRef Tiemensma J, Biermasz NR, Middelkoop HAM, van der Mast RC, Romijn JA, Pereira AM (2010) Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing’s disease. J Clin Endocrinol Metab 95(10):E129–E141PubMedCrossRef
88.
Zurück zum Zitat van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JWA, Roelfsema F, Lamberts SWJ, Romijn JA (2005) Quality of life in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metab 90(6):3279–3286PubMedCrossRef van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JWA, Roelfsema F, Lamberts SWJ, Romijn JA (2005) Quality of life in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metab 90(6):3279–3286PubMedCrossRef
89.
Zurück zum Zitat Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86(1):117–123PubMed Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86(1):117–123PubMed
90.
Zurück zum Zitat Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK (2006) Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab 91(2):447–453PubMedCrossRef Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK (2006) Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab 91(2):447–453PubMedCrossRef
91.
Zurück zum Zitat Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, van Aken MO, Pivonello R, Stalla G, Lamberts SWJ et al (2008) Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur J Endocrinol 158(5):623–630PubMedCrossRef Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, van Aken MO, Pivonello R, Stalla G, Lamberts SWJ et al (2008) Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur J Endocrinol 158(5):623–630PubMedCrossRef
92.
Zurück zum Zitat Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing’s syndrome: a prospective, long-term study. Eur J Endocrinol 154(1):109–118PubMedCrossRef Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing’s syndrome: a prospective, long-term study. Eur J Endocrinol 154(1):109–118PubMedCrossRef
93.
Zurück zum Zitat Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Wägner AM, Rodriguez-Espinosa J, Farrerons J, Webb SM (2009) Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing’s syndrome. J Bone Miner Res 24(11):1841–1846PubMedCrossRef Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Wägner AM, Rodriguez-Espinosa J, Farrerons J, Webb SM (2009) Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing’s syndrome. J Bone Miner Res 24(11):1841–1846PubMedCrossRef
94.
Zurück zum Zitat Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB (2013) Predictors of mortality and long-term outcomes in treated Cushing’s disease: a study of 346 patients. J Clin Endocrinol Metab 98(3):1022–1030PubMedCentralPubMedCrossRef Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB (2013) Predictors of mortality and long-term outcomes in treated Cushing’s disease: a study of 346 patients. J Clin Endocrinol Metab 98(3):1022–1030PubMedCentralPubMedCrossRef
Metadaten
Titel
Characterization of persistent and recurrent Cushing’s disease
verfasst von
Nina K. Sundaram
Alessia Carluccio
Eliza B. Geer
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 4/2014
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-013-0511-3

Weitere Artikel der Ausgabe 4/2014

Pituitary 4/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.